TianYu Bio-Technology Co Current Liabilities
The Current Liabilities of TianYu Bio-Technology Co (603717.SS) as of Oct 12, 2026 is 802.32 M CNY. In the previous year, Current Liabilities was 1.61 B CNY — a change of -50.10% (lower).
Get this data via API
Financial Data API
Current Liabilities
802.32 MCNY
YoY
-50.10%
Last updated:
The TianYu Bio-Technology Co Current Liabilities history
3 Years
10 Years
25 Years
Max
| YEAR | Current Liabilities | YoY |
|---|---|---|
| 802.32 MCNY | -50.10% | |
| 1.61 BCNY | +11.91% | |
| 1.44 BCNY | +19.37% | |
| 1.20 BCNY | -30.16% | |
| 1.72 BCNY | +21.09% | |
| 1.42 BCNY | -6.84% | |
| 1.53 BCNY | -8.94% | |
| 1.68 BCNY | +39.82% | |
| 1.20 BCNY | +57.98% | |
| 759.44 MCNY | -9.29% | |
| 837.18 MCNY | +86.22% | |
| 449.56 MCNY | +16.60% | |
| 385.57 MCNY | +98.24% | |
| 194.50 MCNY | — |
TianYu Bio-Technology Co Stock analysis
Frequently Asked Questions about TianYu Bio-Technology Co stock
Current Liabilities of TianYu Bio-Technology Co is 802.32 M CNY in 2025.
Current Liabilities of TianYu Bio-Technology Co changed from 1.61 B CNY to 802.32 M CNY, representing a -50.10% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Current Liabilities TianYu Bio-Technology Co since 2006 – with annual values, charts, and detailed analysis.
Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.
Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's TianYu Bio-Technology Co historically and in real time.
Balance Sheet — TianYu Bio-Technology Co
All Key Metrics — TianYu Bio-Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth